Figure 5From: MUC1-associated proliferation signature predicts outcomes in lung adenocarcinoma patients Survival in all patients in the database in whom lymph node status is known. Survival is inferior in node-positive patients and in patients who are expressors (MAPS+). MAPS adds significantly to prognostication in both node-negative and node-positive patients.Back to article page